Volta Medical Welcomes Bill Hoffman as the New Executive Chairman of Board

Volta Medical Bolsters Leadership with Bill Hoffman

In an exciting development for the health technology sector, Volta Medical, a trailblazer in AI solutions for electrophysiologists, has appointed Bill Hoffman as the new Executive Chairman of its Board of Directors. This strategic move is aimed at enhancing leadership as the company seeks to expand access to its innovative technology for cardiac ablation globally.

Bill Hoffman's exceptional background in steering innovative ventures makes him an invaluable asset to Volta Medical. Previously, he served as the CEO of Inari Medical, where he played a pivotal role in transforming the company from a nascent concept into a publicly traded entity boasting over $500 million in revenue. The medical industry recognized his efforts when Inari was acquired by Stryker for an impressive $4.9 billion in February 2025.

In welcoming Hoffman, Théophile Mohr-Durdez, CEO and co-founder of Volta Medical, expressed enthusiasm, stating, "We are honored to welcome Bill Hoffman as Executive Chairman. His experience in building and commercializing disruptive medical technologies will be invaluable as we accelerate access to our AI-driven solutions for cardiac ablation."

Hoffman is equally excited about joining the Volta team, noting that the technology has showcased, for the first time ever in the history of ablation, a significant improvement in efficacy outcomes for atrial fibrillation (AFib) patients. "How cool is that? I am thrilled to be part of the mission to positively impact our patients in remarkable ways," he said.

This pivotal appointment comes on the heels of the recent publication of the groundbreaking TAILORED-AF clinical trial, which appeared in Nature Medicine. The trial highlighted that the use of Volta's AI-guided procedures, when combined with traditional pulmonary vein isolation (PVI), led to considerably better outcomes for patients suffering from persistent AF compared to PVI alone.

Atrial Fibrillation (AF) is a pressing health issue, defined by the American Heart Association as an irregular heartbeat that heightens the risk for blood clots, strokes, heart failure, and other serious complications. Globally, an estimated 33 million individuals are affected by AF, yet many remain unaware of the severe nature of this condition. Alarmingly, it's estimated that only 15% of the eligible 2.5 million patients in the U.S. receiving treatment are utilizing catheter ablation.

Volta Medical, founded in 2016 in Marseille, France, aims to revolutionize cardiac arrhythmia management through advanced AI software solutions. The company’s flagship product, the Volta AF-Xplorer™, serves as a digital AI companion for cardiologists, enabling the real-time identification of specific abnormal electrograms during AF and atrial tachycardia procedures. Notably, the AF-Xplorer is designed for compatibility with leading AF mapping and recording systems and has received both U.S. FDA 510(k) clearance and European CE Mark approval.

To address the needs of the underserved AF patient community, Volta Medical has launched an educational initiative called AI for Persistent AF Care. This program aims to heighten awareness about AF treatment options and encourage timely intervention.

With Bill Hoffman at the helm of the Board, Volta Medical is poised to enhance its mission aimed at impacting the lives of AF patients positively through innovative and accessible solutions. As the healthcare landscape continues to evolve, Hoffman's leadership will undoubtedly play a pivotal role in shaping the future of cardiac care with AI technologies.

For more insights about Volta Medical's initiatives and the innovations in the treatment of AF, visit AI for AFib.